Asundexian

→ Tim Coleman has retired as chief technology officer at Eli Lilly , ending a 35-year career with the pharma giant in his hometown of Indianapolis. Coleman held countless positions at Lilly before his appointment as technology chief in December 2022, including VP and information officer for the medicines development unit. Terry Morris , Lilly’s associate VP for clinical tech, posted a photo on LinkedIn as Coleman literally walked out the door for the final time. “My career — and the careers of countless colleagues — has been permanently shaped by his investment in us. The time he gave. The belief he extended. The standard he modeled,” Morris wrote. → Astellas chief strategy officer Adam Pearson is out , leaving a key vacancy at the Japanese pharma. Corporate strategy head Peter Sandor is replacing Pearson on an interim basis. Pearson spent 21 years with Astellas and was elevated to chief strategy officer in 2023, when his predecessor Naoki Okamura took over as CEO. Astellas decided not to pick up AviadoBio ’s gene therapy for frontotemporal dementia this week, despite its continued work in the space. → Nelson Ambrogio will be elevated to US president of Bayer ’s pharmaceutical operations on May 1. Ambrogio joined Bayer in 2007 and Peer Review covered another promotion in 2024, when he replaced Gerd Krueger as president of Bayer’s global radiology business. He also oversaw the US oncology and US women’s healthcare teams. CEO Bill Anderson hasn’t stopped whittling down the headcount at Bayer, which detailed a Phase 3 win for its next-gen blood thinner asundexian in patients who have experienced an ischemic stroke. → Takeda is retooling its board of directors by intending to add J&J vet Paul Stoffels , ex- Humana CEO Bruce Broussard and Eurasia Group senior advisor Koichiro Kimura . CEO-designate Julie Kim will also be on the board by the time she takes over from Christophe Weber in June. Jean Luc Butel , Ian Clark , Yoshiaki Fujimori , Koji Hatsukawa , Emiko Higashi and Michel Orsinger all plan to retire from the board. Takeda is laying off more than 600 US employees as part of a restructuring that could save the company $1.8 billion by fiscal 2028. Peer Review spoke with Stoffels when he retired as CEO of Galapagos last year, which you can read here . → By the way, Galapagos has tapped Gino Santini as chairman of the board, and if shareholders sign off on the appointment, he will succeed Jérôme Contamine on April 28. Santini also chairs the board at Collegium Pharmaceutical and Compass Pathways , and he was SVP of corporate strategy & business development at the end of a long career with Eli Lilly. Santini might not be the only change coming to Galapagos in the near term. As the drug developer seeks to work with Gilead on T cell engagers from Ouro Medicines , it will ask shareholders to ditch the Galapagos brand in favor of a new name : Lakefront Biotherapeutics . CEO Henry Gosebruch is building out a whole new team in Chicago, home to an enviable lakefront path. → It’s another quick stop in the CEO post for Oz Azam , who handed the reins to Lucinda Warren at Cue Biopharma last week on an interim basis. Azam was hired in September 2025 after two years as CEO of Inspirna and a year in the top spot at Empyrean Neuroscience . Warren became chief financial and business officer in February and had been CBO at Cue since September 2024. She engineered a partnership with Boehringer Ingelheim in which the German pharma paid $12 million upfront to license Cue’s bispecific antibody CUE-501 . → Over in Paris, preclinical immunotherapy startup Signadori Bio has found a new CEO. Selwyn Ho will steer the company going forward and will succeed Matthieu Coutet . Ho was previously CEO of T cell receptor company Medigene . Coutet, a partner at Sofinnova , will become chairman of Signadori. → Xaira Therapeutics , the $1 billion AI bet with big aspirations and an all-star cast on the board of directors, has selected Rachel Lane as SVP, business development and operations. Lane is a Versant and Calico alum who was CBO of Belharra Therapeutics , a San Diego startup that hasn’t put out a press release in more than a year and laid off 40% of its employees in December 2024. Xaira president and COO Jeff Jonker was her boss at Belharra. Xaira just revealed a virtual model called X-Cell after mostly toiling in the background in the two years since its launch. “As we continue building models like X-Cell and expanding our platform, strong partnerships will be essential, and Rachel will play a central role in how we connect our science to the broader ecosystem,” Xaira CEO Marc Tessier-Lavigne wrote on LinkedIn. → Ardelyx has tapped Rajani Dinavahi as CMO. According to the Ibsrela and Xphozah maker, Dinavahi will help with “strengthening our pipeline, deepening our medical capabilities, and ensuring we continue to deliver meaningful outcomes for patients.” Dinavahi departed the same post at Atara Biotherapeutics about a year ago. She had spent six years at that T cell immunotherapy company, which received another FDA rejection for its cell therapy in January. → The Winter Olympics in Milan Cortina may be over, but a local biotech is still attracting attention and adding to its team. Italian gene therapy maker AAVantgarde Bio has Philip Lao on its roster as SVP of business development. Lao said in a press release that he will work on “expanding strategic partnership and commercial opportunities” for the biotech’s experimental retinal treatments and other projects. He was previously head of BD at Adverum Biotechnologies , the ophthalmology gene therapy company that Eli Lilly acquired last year. → Royalty Pharma has been in Peer Review three times in the past month for roles focused on China, AI and partnering. Now, it’s losing an executive. Chief accounting officer Kristin Stafford has made her way to Zymeworks as CFO. Her first day at the Canadian cancer biotech was Wednesday. The Jazz – partnered company has shaken up its C-suite over the past year: Its chief medical officer was replaced, and its CFO and general counsel departed . → Genentech ’s US-Belgian molecular glue partner Orionis Biosciences has recruited Giulio Draetta as chief strategy officer. Draetta’s LinkedIn page indicates that he started his new job in January after 14 years at the University of Texas MD Anderson Cancer Center, where he had been CSO since March 2019. Genentech shelled out $105 million upfront last spring in its second deal with Orionis. → Staying in the space, Austrian molecular glue shop Proxygen has introduced Chiara Conti as CSO. She spent more than seven years with Blueprint Medicines and was a senior director when Sanofi scooped up the biotech last year. Like Orionis, Proxygen also has a major pharma partner, teaming up with Merck for up to $2.55 billion almost three years ago today. → Ligand Pharmaceuticals has lined up two VPs of investments and business development: Peter Renehan was bumped up to principal during a six-year run at Blackstone Life Sciences , and Lee Brown worked at Third Bridge Group was global team leader for healthcare. One other Ligand note: Lauren Hay has been promoted to VP of portfolio strategy and investments. → As Daniel Vitt looks for his successor at Immunic , the neuro and gastrointestinal disease biotech has elected Mineralys Therapeutics CEO Jon Congleton to the board of directors. Immunic said in February that Vitt would have a different leadership role when the new CEO is in place. Roche alum Simona Skerjanec has moved up to interim chair of the board. → Vafseo maker Akebia Therapeutics has welcomed Solu Therapeutics CEO Phil Vickers to the board of directors as Steven Gilman retires. Peer Review caught up with Vickers in 2023 when he took the Solu job. Earlier, he led Third Rock ’s Faze Medicines until it shut down two years into its journey. → Inhibikase Therapeutics CEO and Atlas Venture advisor Mark Iwicki is the newest board member at Nocion Therapeutics , which is developing an inhaled chronic cough candidate. Iwicki chairs the board at Q32 Bio and he has spent 11 years on the board at Nimbus Therapeutics .

4月1日，在拜耳举行的处方药全球媒体日活动上，拜耳集团管理委员会成员、处方药事业部全球总裁Stefan Oelrich表示，公司正凭借坚定的科学态度与业务准则，推动变革性战略落地，为当下与未来的增长注入强劲动力。 “得益于强大的处方药产品组合、多元化的研发管线以及日益人工智能化的运营模式，我们有望从2027年起恢复中个位数增长，并从2028年起扩大利润率，到2030年达到30%。”Oelrich在活动中指出。 拜耳处方药执行副总裁、全球产品战略与商业化负责人Christine Roth在活动中表示，公司致力于提供“同类首创”或“同类最佳”的产品。她强调：“过去几年我们做出的大胆选择，正在加速创新，最终将为患者和公司带来实实在在的影响。” 拜耳明确了驱动未来业绩增长的五大核心产品。 一是Asundexian（在研）：一种活化凝血因子XI（XIa）抑制剂。临床研究显示，在非心源性缺血性卒中或高风险短暂性脑缺血发作患者中，联合抗血小板治疗在减少卒中复发方面优于安慰剂。该药物已获美国食品药品监督管理局快速通道资格。 二是达罗他胺（诺倍戈）：首个与雄激素受体抑制剂联合用于转移性激素敏感性前列腺癌的雄激素受体抑制剂。拜耳目标成为第二代雄激素受体抑制剂的全球领导者。 三是非奈利酮（可申达）：首个在五项关键III期研究中显示出心血管和/或肾脏获益的选择性非甾体类盐皮质激素受体拮抗剂。该药已在全球100多个国家获批用于2型糖尿病相关慢性肾脏病，并在美国、日本和欧盟获批用于左心室射血分数≥40%的心力衰竭。 四是Acoramidis（Beyonttra）：用于治疗转甲状腺素蛋白淀粉样变性心肌病的根本原因。该药已在欧盟获批用于野生型或变异型转甲状腺素蛋白淀粉样变性心肌病成年患者。 五是Elinzanetant（Lynkuet）：全球首个双重神经激肽靶向疗法（NK-1和NK-3受体拮抗剂）。在美国获批用于绝经相关中重度血管舒缩症状，在欧盟获批用于绝经相关或乳腺癌辅助内分泌治疗引起的中重度血管舒缩症状。 拜耳处方药执行副总裁、全球研发负责人Christian Rommel介绍，2025年公司取得了3项新产品获批、2项新适应症获批、6项III期临床试验积极结果的突破性成绩。“2026年，我们预计将在心血管和肿瘤等核心治疗领域的精准治疗、再生细胞与基因疗法，以及分子影像等多个领域取得关键里程碑，进一步验证以创新驱动影响的战略。” 在精准药物研发方面，拜耳正在推进多项前沿项目：用于晚期转移性去势抵抗性前列腺癌的靶向α疗法225Ac-PSMA-Trillium；全球首个进入临床试验的WRN共价抑制剂VVD-214，针对微卫星不稳定性高表达的实体瘤；用于控制房颤患者心脏电活动的高选择性GIRK4抑制剂；以及已在中美获得突破性疗法认定的HER2突变非小细胞肺癌治疗药物塞伐艾替尼。 在基因疗法与细胞疗法领域，拜耳同样取得重要进展。针对射血分数降低的心力衰竭的基因疗法AB-1002已完成II期临床随机分组；针对帕金森病的基因疗法Ametefgene parvec和细胞疗法Bemdaneprocel均处于临床开发阶段；用于原发性感光细胞疾病的OpCT-001已获美国食品药品监督管理局快速通道资格和孤儿药认定。 在医学影像领域，拜耳持续推动创新。新一代低剂量大环状钆基MRI对比剂Gadoquatrane已于2026年3月在日本获批，与现有制剂相比每次检查可减少高达60%的钆剂量。此外，在研的泛淀粉样分子影像示踪剂AT-01和AT-05有望为心脏淀粉样变性等疾病的准确诊断提供新的解决方案。 拜耳处方药研发数据科学与人工智能高级副总裁Sai Jasti表示，公司目标到2030年利用人工智能将研发生产力提升40%。通过构建结合匿名化数据与人工智能分析的全球生态系统，并与范德比尔特大学医学中心、FinnGen、PRECISE及Cradle等机构建立战略合作，拜耳正加速心血管和肾脏病等关键领域的药物研发进程。人工智能已日益融入拜耳从端到端规划到智能工具套件的整个价值链。